Belgium-based Multiplicom has announced it is introducing three new somatic mutation detection kits, which will enable the implementation of personalized cancer treatment at an unprecedented level.
The new somatic mutation detection kits incorporates Multiplicom’s proprietary MASTR technology: epidermal growth factor (EGFR 18-21); gastro-intestinal stromal tumors (GIST) (cKIT, PDGFRA) and somatic panel 1 (KRAS, NRAS, BRAF) and complement Multiplicom’s MASTR product line that can be used in combination with all commercial bench top MPS instruments.
These three new kits will allow the PCR amplification of genes known to be frequently mutated in tumor tissue of highly prevalent cancers of the gastro-intestinal track, colon, lung and skin.
The DNA sequence of the genes can be determined based on the PCR amplified material, allowing clinicians to identify all mutations and subsequently select the most effective treatment for the patient.
Multiplicom CEO Dr Dirk Pollet noted the introduction of the new kits establishes the company as a European leader in the implementation of MPS in the routine labs, and the enabling of personalized medicine.
"Multiplicom’s products are simple, easy to use, only require standard equipment and are compatible with MPS equipment from Roche, Life Technologies and Illumina.
Our products provide answers to physicians and patients by linking genetics to health and disease and subsequently Multiplicom’s products are able to improve treatment and quality of life, without adding to the overall cost of health care," Pollet noted.